AbbVie combines advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people’s lives. Read through our press releases to see our latest efforts to improve patient care.

If you are a member of the news media and have questions or need additional information, please contact our Communications Team.

   Clear Filter

Apr 07, 2014

AbbVie to Host First-Quarter Earnings Conference Call

NORTH CHICAGO, Ill., April 7, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its first-quarter 2014 financial results on Friday, April 25, 2014, before the market opens.

Mar 24, 2014

AbbVie to Present Detailed Results from Phase III Studies in Patients with Chronic Hepatitis C at the 2014 International Liver Congress™

NORTH CHICAGO, Ill., March 24, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will present new data from its phase III hepatitis C development program at the 2014 International Liver Congress™ (ILC) in London, April 9-13. Detailed results from the SAPPHIRE-I, SAPPHIRE-II, PEARL-III, and TURQUOISE-II studies will be presented at the ILC on April 10-12.  

Mar 20, 2014

AbbVie Initiates New Clinical Trial to Evaluate HUMIRA® (adalimumab) for the Treatment of Fingernail Psoriasis in Patients with Moderate to Severe Chronic Plaque Psoriasis

NORTH CHICAGO, Ill., March 20, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the initiation of a pivotal Phase 3 clinical trial that will evaluate the use of HUMIRA® (adalimumab) as a treatment for fingernail psoriasis in patients with moderate to severe chronic plaque psoriasis, an area of unmet need. Currently there are no approved treatments for fingernail psoriasis.

Mar 03, 2014

AbbVie to Present Late-breaker PEARL-III Study in Patients with Chronic Hepatitis C at the 21st Conference on Retroviruses and Opportunistic Infections

BOSTON, March 3, 2014 /PRNewswire/ -- The first detailed results from AbbVie's (NYSE: ABBV) pivotal phase III study, PEARL-III, were presented today as part of the 21st Conference on Retroviruses and Opportunistic Infections (CROI) press conference and will also be presented as a late-breaker at the conference on March 4. PEARL-III evaluated the efficacy and safety of 12 weeks of treatment with AbbVie's investigational therapy with or without ribavirin (RBV) in non-cirrhotic, adult patients with chronic genotype 1b (GT1b) hepatitis C virus (HCV) infection who were new to treatment.

Feb 26, 2014

AbbVie to Present at Barclays Global Healthcare Conference 2014

NORTH CHICAGO, Ill., Feb. 26, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Barclays Global Healthcare Conference 2014 on Thursday, March 13, 2014. Bill Chase, executive vice president and chief financial officer, will take part in a question and answer session at 7:30 a.m. Central time.

Feb 20, 2014

AbbVie Increases Quarterly Dividend

NORTH CHICAGO, Ill., Feb. 20, 2014 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) increased the company's quarterly cash dividend by 5 percent from $0.40 per share to $0.42 per share. 

Feb 20, 2014

AbbVie Announces New Art Gallery Designed To Provide Perspectives On The Impact Of Chronic Inflammatory Diseases

NORTH CHICAGO, Ill., Feb. 20, 2014 /PRNewswire/ -- AbbVie today announced the launch of 'Perspectives – Art, Inflammation and Me', an initiative designed to add a different dimension to the current understanding of immune-mediated inflammatory diseases (IMIDs) and their impact on patients and society.  More than 100 unique artistic expressions from the initiative are being debuted at the 9th Congress of the European Crohn's and Colitis Organisation (ECCO) in Copenhagen, Denmark from February 20th to 22nd.

Feb 19, 2014

AbbVie to Present at Cowen 34th Annual Health Care Conference

NORTH CHICAGO, Ill., Feb. 19, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Cowen and Company 34th Annual Health Care Conference on Wednesday, March 5, 2014. Bill Chase, executive vice president and chief financial officer, will take part in a question and answer session at 7:40 a.m. Central time.

Feb 05, 2014

AbbVie Expands Manufacturing Presence with US$320 Million Investment in Singapore

NORTH CHICAGO, Ill., Feb. 5, 2014 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV) announces a US$320 million [approximately S$400 million] investment to establish operations in Singapore for small molecule and biologics active drug substance manufacturing. The completed facility will provide manufacturing capacity for emerging compounds within AbbVie's oncology and immunology pipeline to serve markets globally.